Publications by authors named "Ghfran Abdulrahman Bokhari"
Article Synopsis
- NAFLD is a growing health concern with no specific FDA-approved treatments currently available.
- A search of ClinicalTrials.gov identified 31 eligible interventional studies, with 19 selected for detailed evaluation, primarily from Korea and China.
- Medications like metformin, Exenatide, and Pioglitazone were among the most studied interventions, highlighting the need for continued research into effective treatments for NAFLD.
Background: Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic inflammatory conditions affecting the gastrointestinal tract. To achieve and sustain remission, effective treatment strategies are necessary. Ustekinumab, a biologic agent targeting interleukin-12 and interleukin-23, has emerged as a significant therapeutic option for moderate to severe IBD.
View Article and Find Full Text PDF